

Stanford



Sigurdis Haraldsdottir

CONTACT INFORMATION

- **University Administrative Contact**

Kristin Schjaerve - Administrative Assistant

Email kschjaer@stanford.edu

Bio

BIO

Dr. Sigurdis Haraldsdottir, M.D., Ph.D. is an Assistant Professor of Medicine at Stanford University School of Medicine. She received her medical degree and master's degree in medical sciences from the University of Iceland. She did her Internal Medicine training at Boston University Medical Center and training in Medical Oncology at the Ohio State University, before joining the faculty at Stanford. Her clinical and research focus is in gastrointestinal malignancies with a focus on mismatch repair deficient cancers, particularly colorectal cancer. She is conducting population-based research on Lynch syndrome - an inherited cancer syndrome, and recently completed a nation-wide study on Lynch syndrome in Iceland. She received her Ph.D. in Medical Sciences in 2017 from the University of Iceland. Her interests also focus on investigating colorectal cancer genomics, and their effect on outcomes and treatment implications.

ACADEMIC APPOINTMENTS

- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Pelotonia Fellowship Award, Ohio State University (1/2013)
- Workshop in Cancer Therapeutics and Drug Development, Leesburg, Virginia, Merrill J. Egorin (11/2014)
- Obrine Weaver Award, Ohio State University (3/2014)
- Graduated Top of Class, University of Iceland, Faculty of Medicine (6/2004)
- Outstanding Achievement Award in Internal Medicine Residency, Landspítali University Hospital, Reykjavik, Iceland (6/2008)
- Cancer Education Consortium Molecular and Translational Oncology Workshop, Fort Myers, Florida (6/2013)
- Outstanding Clinical Care by Hematology & Oncology Fellow Award, Ohio State University Medical Center (6/2013)
- Outstanding Research, Hematology & Oncology Fellow Award at Ohio State University Medical Center (6/2014)
- Achievement Award, Association of Female Physicians in Iceland (7/2004)
- Travel Grant Recipient, 2014 Colon Cancer Challenge Foundation (7/2014)
- Vail Workshop, 2014 ASCO/AACR (7/2014)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair, Not Recruiting
- Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy, Not Recruiting
- Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer, Not Recruiting
- Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177), Not Recruiting

Publications

PUBLICATIONS

- **Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Burkart, J., Owen, D., Shah, M. H., Abdel-Misih, S. R., Roychowdhury, S., Wesolowski, R., Haraldsdóttir, S., Reeser, J. W., Samorodnitsky, E., Smith, A., Konda, B.
2018; 16 (9): 1035–40
- **Histology of colorectal adenocarcinoma with Check for double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome** *HUMAN PATHOLOGY*
Hemming, J. A., Pearlman, R., Haraldsdóttir, S., Knight, D., Jonasson, J., Pritchard, C. C., Hampel, H., Frankel, W. L.
2018; 78: 125–30
- **Promising New Agents for Colorectal Cancer** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Das, S., Ciombor, K. K., Haraldsdóttir, S., Goldberg, R. M.
2018; 19 (6): 29
- **Management of Borderline Resectable Pancreatic Cancer.** *International journal of radiation oncology, biology, physics*
Toesca, D. A., Koong, A. J., Poultsides, G. A., Visser, B. C., Haraldsdóttir, S. n., Koong, A. C., Chang, D. T.
2018; 100 (5): 1155–74
- **The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy** *SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY*
Halldórsson, M., Hauptmann, M., Snaebjörnsson, P., Haraldsdóttir, K., Aspelund, T., Gudmundsson, E., Gudnason, V., Jonasson, J., Haraldsdóttir, S.
2018; 53 (8): 972–75
- **Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.** *The oncologist*
Patel, S. A., Longacre, T. A., Ladabaum, U. n., Lebensohn, A. n., Lin, A. Y., Haraldsdóttir, S. n.
2018
- **Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy?** *CURRENT COLORECTAL CANCER REPORTS*
Haraldsdóttir, S., Goldberg, R. M.
2017; 13 (6): 419–28
- **Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2** *NATURE COMMUNICATIONS*
Haraldsdóttir, S., Rafnar, T., Frankel, W. L., Einarsson, S., Sigurdsson, A., Hampel, H., Snaebjörnsson, P., Masson, G., Weng, D., Arngrimsson, R., Kehr, B., Yilmaz, A., Haraldsson, et al
2017; 8
- **Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.** *Gastroenterology*
Cohen, S. A., Turner, E. H., Beightol, M. B., Jacobson, A., Gooley, T. A., Salipante, S. J., Haraldsdóttir, S., Smith, C., Scroggins, S., Tait, J. F., Grady, W. M., Lin, E. H., Cohn, et al
2016; 151 (3): 440-447 e1
- **Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.** *Genetics in medicine*
Haraldsdóttir, S., Hampel, H., Wu, C., Weng, D. Y., Shields, P. G., Frankel, W. L., Pan, X., De la Chapelle, A., Goldberg, R. M., Bekaii-Saab, T.

2016; 18 (9): 863-868

- **Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome-Associated Neoplasms: ?A Recommendation for Screening Synchronous/ Metachronous Neoplasms.** *American journal of clinical pathology*
Roth, R. M., Haraldsdottir, S., Hampel, H., Arnold, C. A., Frankel, W. L.
2016; 146 (1): 50-56
- **Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.** *Familial cancer*
Haraldsdottir, S., Roth, R., Pearlman, R., Hampel, H., Arnold, C. A., Frankel, W. L.
2016; 15 (2): 253-260
- **Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.** *JAMA dermatology*
Haraldsdottir, S. n., Bertino, E. n., Haglund, K. n., Kaffenberger, B. n., Shah, M. H.
2016; 152 (5): 587-89
- **Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations** *GASTROENTEROLOGY*
Haraldsdottir, S., Hampel, H., Tomsic, J., Frankel, W. L., Pearlman, R., De la Chapelle, A., Pritchard, C. C.
2014; 147 (6): 1308-?
- **New era for treatment in differentiated thyroid cancer** *LANCET*
Haraldsdottir, S., Shah, M. H.
2014; 384 (9940): 286-288
- **Prostate cancer incidence in males with Lynch syndrome** *GENETICS IN MEDICINE*
Haraldsdottir, S., Hampel, H., Wei, L., Wu, C., Frankel, W., Bekaii-Saab, T., De la Chapelle, A., Goldberg, R. M.
2014; 16 (7): 553-557
- **How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?** *Current colorectal cancer reports*
Ciombor, K. K., Haraldsdottir, S. n., Goldberg, R. M.
2014; 10 (4): 372-79
- **Adjuvant Chemotherapy Should Not Routinely Be Recommended to Patients with Stage II Colon Cancers that Manifest Microsatellite Instability.** *GI ASCO Educational Book*
Haraldsdottir, S.
2014
- **An update on clinical trials of targeted therapies in thyroid cancer** *CURRENT OPINION IN ONCOLOGY*
Haraldsdottir, S., Shah, M. H.
2014; 26 (1): 36-44
- **Integrating anti-EGFR therapies in metastatic colorectal cancer.** *Journal of gastrointestinal oncology*
Haraldsdottir, S., Bekaii-Saab, T.
2013; 4 (3): 285-298
- **What is the optimal neo-adjuvant treatment for liver metastasis?** *THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY*
Haraldsdottir, S., Wu, C., Bloomston, M., Goldberg, R. M.
2013; 5 (4): 221-234
- **Case of Sorafenib-Induced Thyroid Storm** *JOURNAL OF CLINICAL ONCOLOGY*
Haraldsdottir, S., Li, Q., Villalona-Calero, M. A., Olencki, T. E., Kendra, K., Ing, S. W.
2013; 31 (16): E262-E264
- **Advances in systemic therapy for advanced pancreaticobiliary malignancies.** *F1000Research*
Halfdanarson, T. R., Haraldsdottir, S., Borad, M. J.
2013; 2: 105-?
- **Cancer of the Colon and Rectum: A Decade of Progress** *GI ASCO Educational Book*
Haraldsdottir, S.
2013
- **Clinical Indications for ziv-Aflibercept in Colorectal Cancer.** *International Journal of Targeted Therapies in Cancer*

Haraldsdottir, S.
2013

- **Recent advances in treatment of metastatic colorectal cancer.** *Clinical Investigation*
Haraldsdottir, S.
2012
- **A single institutional experience with panitumumab in metastatic colorectal cancer** *Journal of Cancer Therapy*
Haraldsdottir, S.
2012
- **Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population** *EUROPEAN JOURNAL OF RADIOLOGY*
Haraldsdottir, S., Gudnason, T., Sigurdsson, A. F., Gudjonsdottir, J., Lehman, S. J., Eyjolfsson, K., Scheving, S. S., Gibson, C. M., Hoffmann, U., Jonsdottir, B., Andersen, K.
2010; 76 (2): 188-194
- **Clinical evaluation and stress test have limited value in the diagnosis of in-stent restenosis** *SCANDINAVIAN CARDIOVASCULAR JOURNAL*
Andersen, K., Steinporsdottir, S. D., Haraldsdottir, S., Gudnason, T.
2009; 43 (6): 402-407
- **Diagnostic accuracy of 64-slice computed tomography compared with coronary angiography** *LAEKNAÐLADID*
Valgeirsdottir, I. R., Haraldsdottir, S., Scheving, S. S., Guojonsdottir, J., Sigurosson, A. F., Guonason, P., Eyjolfsson, K., Jonsdottir, B., Andersen, K.
2008; 94 (3): 199-205
- **Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro** *PLANTA MEDICA*
Haraldsdottir, S., Gudlaugsdottir, E., Ingolfsdottir, K., Ogmundsdottir, H. M.
2004; 70 (11): 1098-1100
- **Effects of tenuiorin and methyl orsellinate from the lichen *Peltigera leucophlebia* on 5-/15-lipoxygenases and proliferation of malignant cell lines in vitro** *PHYTOMEDICINE*
Ingolfsdottir, K., Gudmundsdottir, G. F., Ogmundsdottir, H. M., Paulus, K., Haraldsdottir, S., Kristinsson, H., Bauer, R.
2002; 9 (7): 654-658